脐带间充质干细胞移植对帕金森病的临床疗效观察

Efficacy and safety of umbilical cord mesenchymal stem cell transplantation on the treatment of Parkinson's disease

目的探讨脐带间充质干细胞(UC-MSC)移植治疗帕金森病(PD)的临床效果及安全性。方法选择福州总医院干细胞治疗科收治的20例经鞘内注射UC-MSC治疗原发性PD患者为实验组,本院神经内科收治的20例经口服左旋多巴治疗原发性PD患者为对照组。采用PD统一评分量表(UPDRS)对患者治疗前及治疗后1个月、3个月、6个月进行量化评分。采用两独立样本t检验进行统计分析比较实验组与对照组差异。结果实验组20例患者临床症状缓解程度较对照组明显,实验组与对照组治疗前UPDRS评分与治疗后1个月、3个月、6个月的UPDRS评分的差值分别为[(11.45±2.01)分,(6.25±1.07)分,t=26.12,P=0.00],[(16.1±2.65)分,(7.6±1.47)分,t=23.19,P=0.00],[(20.45±3.28)分,(8.45±1.85)分,t=20.44,P=0.00],差异均有统计学意义。结论鞘内注射UC-MSC治疗PD的临床疗效优于单纯口服左旋多巴片治疗PD。

Objective To evaluate the efficacy and safety of umbilical cord mesenchymal stem cell transplantation on the treatment of Parkinson＇s disease. Methods Twenty patients with Parkinson＇s disease were treated with umbilical cord mesenchymal stem cells through the intrathecal injection; 20 cases with Parkinson＇s disease treated with levodopa served as control. Patients were evaluated by unified Parkinson disease rating scale at baseline, 1 month, 3 months, and 6 months after the treatment, t-test was used to analyze the difference. Results The experimental group had have greater improvement than the control group at 1 month,3 months,6 months, The difference values（d） of the scores before the treatment and 1 month,3 monthes,6 monthes after the treatment of experimental group and control group are respectively （11.45士2.01, 6.25 士 1.07, t = 26.12, P = 0.00）, （ 16.1 士2.65, 7.6 士 1.47, t = 23.19, P = 0.00）, （20.45 士3.28, 8.45士 1.85, t = 20.44, P = 0.00）, the difference was statistically significant （P 〈 0.05）. Conclusions Umbilical cord mesenchymal stern cell through the intrathecal iniection was more effective than levodopa in treating Parkinson＇s disease.